Around-the-clock ambulatory blood pressure monitoring is required to properly diagnose resistant hypertension and assess associated vascular risk

Current Hypertension Reports

Volumn 16, Issue 7, 2014, Pages

  Hermida, Ramón C ^a,d   Ayala, Diana E ^a   Ríos, María T ^a,b   Fernández, José R ^a   Mojón, Artemio ^a   Smolensky, Michael H ^c  

^a UNIVERSITY OF VIGO   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

^c The University of Texas at Austin   (United States)

^d Bioengineering and Chronobiology Laboratories   (Spain)

Author keywords

Ambulatory blood pressure monitoring; Asleep blood pressure; Bedtime hypertension chronotherapy; Cardiovascular risk; Resistant hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ALBUMINURIA; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MONITORING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLASSIFICATION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG USE; EVENT FREE SURVIVAL; FOLLOW UP; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MASKED HYPERTENSION; MONOTHERAPY; MORBIDITY; OBESITY; PRIMARY MEDICAL CARE; PROGNOSIS; RESISTANT HYPERTENSION; SLEEP DISORDERED BREATHING; SLEEP TIME; SUDDEN CARDIAC DEATH; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; TRANSIENT ISCHEMIC ATTACK; WAKEFULNESS; COMPLICATION; HYPERTENSION; PHYSIOLOGY; PROCEDURES; RISK; SLEEP; TIME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; HUMANS; HYPERTENSION; RISK; SLEEP; TIME FACTORS;

EID: 84901738104     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0445-9     Document Type: Article

References (88)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52. (Pubitemid 37553153)
2. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-19.
3. Fagard RH. Resistant hypertension. Heart. 2012;98:254-61.
4. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357.
5. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001;19:2063-70. (Pubitemid 33035812)
6. Hernández del Rey R, Armanio P, Martín M, Sánchez P, Cárdenas P, Pardell H. Target organ damage and cardiovascular risk profile in resistant hypertension. Influence of the white coat effect. Blood Press Monit. 1998;3:331-7. (Pubitemid 29141972)
7. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension. Hypertension. 1998;31:712-8.
8. • Salles GF, Cardoso CR,Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168:2340-6. This study showed that higher nighttime BP was the strongest predictor of CVD morbidity and mortality in RH patients.
9. • Ayala DE, Hermida RC, Mojón A, Fernández JR. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol Int. 2013;30:340 - 52. This study documented: (i) bedtime- versus upon-awakening hypertension treatment significantly reduced CVD risk in patients with RH; and (ii) attenuation of the asleep SBP mean was an independent prognostic marker of reduced CVD risk, thus validating asleep BP as a novel therapeutic goal in RH.
10. Perloff D, Sokolow M, Cowan R. The prognostic value of ambulatory blood pressures. JAMA. 1983;249:2792-8. (Pubitemid 13093711)
11. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801. (Pubitemid 24363980)
12. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407-15. (Pubitemid 36682819)
13. • Hermida RC, Ayala DE, Mojón A, Fernández JR. Decreasing sleeptime blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011;58:1165-73. This report, derived from the MAPEC study showed for the very first time that attenuation of the asleep SBP mean, but not the awake BP mean or clinic BP measurements, was significantly associated with reduced CVD risk, thus validating asleep BP as a novel therapeutic goal.
14. Minutolo R, Agarwal R, Borrelli S, et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med. 2011;171:1090-8.
15. Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. Circadian rhythms and cardiovascular health. Sleep Med Rev. 2012;16:151-66.
16. • Fabbian F, Smolensky MH, Tiseo R, Pala M, Manfredini R, Portaluppi F. Dipper and non-dipper blood pressure 24-hour patterns: circadian rhythm-dependent physiologic and pathophysiologic mechanisms. Chronobiol Int. 2013;30:17-30. This paper reviewed the underlying exogenous and endogenous mechansisms of 24-hour SBP and DBP patterning and helped to explain reported differences in effects of morning versus evening hypertension treatment strategies.
17. Hermida RC, Fernández JR, Ayala DE, Mojón A, Alonso I, Smolensky M. Circadian rhythm of double (rate-pressure) product in healthy normotensive young subjects. Chronobiol Int. 2001;18:475-89. (Pubitemid 32666418)
18. Hermida RC, Calvo C,Ayala DE,Mojón A, López JE. Relationship between physical activity and blood pressure in dipper and nondipper hypertensive patients. J Hypertens. 2002;20:1097-104. (Pubitemid 34913627)
19. Smolensky MH, Hermida RC, Castriotta RJ, Portaluppi F. Role of sleep-wake cycle on blood pressure circadian rhythms and hypertension. Sleep Med. 2007;8:668-80. (Pubitemid 47192885)
20. • Hermida RC, Smolensky MH, Ayala DE, et al. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Joint recommendations from the International Society for Chronobiology (ISC), American Association of Medical Chronobiology and Chronotherapeutics (AAMCC), Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk (SECAC), Spanish Society of Atherosclerosis (SEA), and Romanian Society of Internal Medicine (RSIM). Chronobiol Int. 2013;30:355-410. These guidelines provide up-to-date recommendations for the proper use of ABPM to assess CVD risk and to guide therapeutic intervention, including in RH patients.
21. Hermida RC, Ayala DE, Fernández JR, Mojón A. Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction. Chronobiol Int. 2013;30:68-86.
22. Nakano S, Fukuda M, Hotta F, et al. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal events in NIDDM subjects. Diabetes. 1998;47:1501-6. (Pubitemid 28396956)
23. Sturrock NDC, George E, Pound N, Stevenson J, Peck GM, Sowter H. Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet Med. 2000;17:360-4. (Pubitemid 30353800)
24. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38:852-7. (Pubitemid 34258682)
25. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002;20:2183-9. (Pubitemid 35388236)
26. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-61. (Pubitemid 40946507)
27. Ingelsson E, Bjorklund-Bodegard K, Lind L, Arnlov J, Sundstrom J. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA. 2006;295:2859-66. (Pubitemid 43974183)
28. Astrup AS, Nielsen FS, Rossing P, et al. Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens. 2007;25:2479-85. (Pubitemid 350060387)
29. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370:1219-29. (Pubitemid 47503300)
30. Brotman DJ, Davidson MB, Boumitri M, Vidt DG. Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens. 2008;21:92-7.
31. Muxfeldt ES, Salles GF. Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension? J Hypertens. 2008;26:878-84. (Pubitemid 351520974)
32. Eguchi K, Pickering TG, Hoshide S, et al. Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes.Am J Hypertens. 2008;21:443-50. (Pubitemid 351450870)
33. Hermida RC, Ayala DE, Mojón A, Fernández JR. Blunted sleeptime relative blood pressure decline increases cardiovascular risk independent of blood pressure level -the "normotensive nondipper" paradox. Chronobiol Int. 2013;30:87-98.
34. Kikuya M, Ohkubo T, Asayama K, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension. 2005;45:240-5. (Pubitemid 40179967)
35. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Predictors of all-causemortality in clinical ambulatory monitoring. Unique aspects of blood pressure during sleep. Hypertension. 2007;49:1235-41. (Pubitemid 46809363)
36. Bouhanick B, Bongard V, Amar J, Bousquel S, Chamontin B. Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. Diabetes Metab. 2008;34:560-7.
37. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55-61. (Pubitemid 350307104)
38. Fan HQ, Li Y, Thijs L, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28:2036-45.
39. Hermida RC, Ayala DE,Mojón A, Fernández JR. Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am J Hypertens. 2012;25:325-34.
40. Hermida RC, Ayala DE,Mojón A, Fernández JR. Sleep-time blood pressure and the prognostic value of isolated-office and masked hypertension. Am J Hypertens. 2012;25:297-305.
41. Muxfeldt ES, Cardoso CR, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med. 2009;169:874-80.
42. Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18:1422-8. (Pubitemid 41566669)
43. Hermida RC. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study. Chronobiol Int. 2007;24:749-75. (Pubitemid 47263103)
44. • Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27:1629-51. The MAPEC study is the first and only prospective trial investigating the association among prognostic ABPM parameters, CVD risk, and time-specified hypertension treatment strategy. Results indicated that routine ingestion of the full daily dose of ≥1 BPlowering medications at bedtime, compared to ingestion of all medications upon awakening, resulted in significantly lower adjusted HR of total and major CVD events.
45. Hermida RC, Ayala DE,Mojón A, Fernández JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34:1270-6.
46. Hermida RC, Ayala DE, Mojón A, Fernández JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22:2313-21.
47. Hermida RC, Ayala DE, Mojón A, Fernández JR. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications. Chronobiol Int. 2013;30:315-27.
48. Hermida RC, Ayala DE, Mojón A, Fernández JR. Role of time-ofday of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk. Chronobiol Int. 2013;30:328-39.
49. Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. Ambulatory blood pressure monitoring: Importance of sampling rate and duration-48 versus 24 hours-on the accurate assessment of cardiovascular risk. Chronobiol Int. 2013;30:55-67.
50. Gustavsen PH, Hoegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study. J Hum Hypertens. 2003;17:811-7. (Pubitemid 38028637)
51. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring. 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508-15. (Pubitemid 41040294)
52. Verdecchia P, Roboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203-8. (Pubitemid 40179961)
53. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25:2193-8. (Pubitemid 47537908)
54. Bobrie G, Clerson P, Ménard J, Postel-Vinay N, Chatellier G, Plouin PF. Masked hypertension: a systematic review. J Hypertens. 2008;26:1715-25.
55. Angeli F, Reboldi G, Verdecchia P. Masked hypertension: evaluation, prognosis, and treatment. Am J Hypertens. 2010;23:941-8.
56. Pierdomenico SD, Cuccurullo F. Prognostic value ofwhite-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta-analysis. Am J Hypertens. 2011;24:52-8.
57. Mezzetti A, Pierdomenico SD, Costantini F, et al. White-coat resistant hypertension. Am J Hypertens. 1997;10:1302-7. (Pubitemid 28005355)
58. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14:1263-9. (Pubitemid 33151484)
59. Veglio F, Rabbia F, Riva P, et al. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin Exp Hypertens. 2001;23:203-11. (Pubitemid 32374602)
60. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit. 2003;8:181-5. (Pubitemid 41623175)
61. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-902.
62. Brambilla G, Bombelli M, Seravalle G, et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens. 2013;31:2018-24.
63. Muxfeldt ES, Salles GF. How to use ambulatory blood pressure monitoring in resistant hypertension. Hypertens Res. 2013;36:385-9.
64. Ríos MT, Domínguez-Sardiña M, Ayala DE, et al. Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Chronobiol Int. 2013;30:207-20.
65. Ayala DE, Moyá A, Crespo JJ, et al. Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes. Chronobiol Int. 2013;30:99-115.
66. Crespo JJ, Piñeiro L, Otero A, et al. Administration-time-dependent effects of hypertension treatment on ambulatory blood pressure in patients with chronic kidney disease. Chronobiol Int. 2013;30:159-75.
67. • Hermida RC, Ríos MT, Crespo JJ, et al. Treatment-time regimen of hypertension medications significantly affects ambulatory blood pressure and clinical characteristics of patients with resistant hypertensions. Chronobiol Int. 2013;30:192-206. This paper is a comprehensive review of the advanatages of the bedtime treatment strategy over the traditional morning-time regimen as a means of controlling ambulatory BP of patients labeled as resistant to therapy.
68. Mojón A, Ayala DE, Piñeiro L, et al. Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol Int. 2013;30:145-58.
69. Moyá A, Crespo JJ, Ayala DE, et al. Effects of time-of-day of hypertension treatment on ambulatory blood pressure and clinical characteristics of patients with type 2 diabetes. Chronobiol Int. 2013;30:116-31.
70. Friedman O, Logan AG. Nocturnal blood pressure profiles among normotensive, controlled hypertensive and refractory hypertensive subjects. Can J Cardiol. 2009;25:e312-6.
71. Crespo C, Fernández JR, Aboy M,Mojón A. Clinical application of a novel automatic algorithm for actigraphy-based activity and rest period identification to accurately determine awake and asleep ambulatory blood pressure parameters and cardiovascular risk. Chronobiol Int. 2013;30:43-54.
72. Bruguerolle B, Lemmer B. Recent advances i n chronopharmacokinetics: methodological problems. Life Sci. 1993;52:1809-24.
73. Gupta SK, Yih BM, Atkinson L, Longstreth J. The effect of food, time of dosing and body composition on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil. J Clin Pharmacol. 1995;35:1083-93.
74. Labrecque G, Beauchamp D. Rhythms and pharmacokinetics. In: Redfern P, editor. Chronotherapeutics. London: Pharmaceutical Press; 2003. p. 75-110.
75. Okyar A, Dressler C, Hanafy A, Baktir G, Lemmer B, Spahn- Langguth H. Circadian variations in exsorptive transport: in-situ intestinal perfusion data and in-vivo relevance. Chronobiol Int. 2012;29:443-53.
76. Smolensky MH, Siegel RA, Haus E, Hermida RC, Portaluppi F. Biological rhythms, drug delivery, and chronotherapeutics. In: Siepmann J, Siegel RA, Rathbone MJ, editors. Fundamentals and applications of controlled release drug delivery. Heildelberg: Springer-Verlag; 2012. p. 359-443.
77. Hermida RC, Ayala DE, Fernández JR, Portaluppi F, Fabbian F, Smolensky MH. Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am J Hypertens. 2011;24:383-91.
78. Hermida RC, Ayala DE, Fernández JR, et al. Administration- timedifferences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int. 2013;30:280-314.
79. Hermida RC, Ayala DE, Smolensky MH, et al. Chronotherapeutics of conventional blood pressure-lowering medications: simple, lowcost means of improving management and treatment outcomes of hypertensive-related disorders. Curr Hypertens Rep. 2014;16:412.
80. Cugini P. The treatability of refractory or resistant hypertension by personalized antihypertensive chronotherapy based on ambulatory monitoring of the arterial pressure. Recenti Prog Med. 1996;87:51- 7.
81. Hermida RC, Ayala DE, Calvo C, et al. Effects of the time of day of antihypertensive treatment on the ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension. 2005;46:1053-9.
82. Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension. 2008;51:69- 76.
83. Hermida RC, Ayala DE,Mojón A, Fernández JR. Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. Am J Hypertens. 2010;23:432-9.
84. Almirall J, Comas L, Martínez-Ocaña JC, Roca S, Arnau A. Effects of chronotherapy on blood pressure control in non-dipper patients with refractory hypertension. Nephrol Dial Transplant. 2012;27:1855-9.
85. Degaute JP,Van de Borne P,Kerkhofs M,Dramaix M, Linkowski P. Does non-invasive ambulatory blood pressure monitoring disturb sleep? J Hypertens. 1992;10:879-85.
86. Musso NR, Vergassola C, Barone C, Lotti G. Ambulatory blood pressure monitoring: how reproducible is it? Am J Hypertens. 1997;10:936-9. (Pubitemid 27380960)
87. Mochizuki Y, Okutani M, Donfeng Y, Iwasaki H, Takusagawa M, Kohno I, et al. Limited reproducibility of circadian variation in blood pressure dippers and nondippers. Am J Hypertens. 1998;11:403-9. (Pubitemid 28231451)
88. James GD, Pickering TG, Yee LS, Harshfield GA, Riva S, Laragh JH. The reproducibility of average, ambulatory, home, and clinical pressures. Hypertension. 1988;11:545-9.